icon-folder.gif   Conference Reports for NATAP  
 
  HIV Glasgow 2020, 5-8 October
Virtual Meeting
Back grey_arrow_rt.gif
 
 
 
Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449)
 
 
  Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
 
Maggiolo F, RizzardiniG, Molina JM, Pulido F, De Wit S, VandekerckhoveL, BerenguerJ,Blair C, Chuck S, PiontkowskyD, Martin H, McNichollI, HaubrichR, Gallant J Gilead Sciences, Inc., Foster City, California, USA

1009201

1009202

1009203

1009204